Dry powder formulation of azithromycin for COVID-19 therapeutics

References

• Abaleke, E., and Abbas, M., et al., 2021. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The lancet, 397 (10274), 605–612.
   Google Scholar
• Al-Rimawi, F., and Kharoaf, M., 2010. Analysis of azithromycin and its related compounds by RP-HPLC with UV detection. Journal of chromatographic science, 48 (2), 86–90.
   PubMed Web of Science ®Google Scholar
• ANTICOV. 2021. An open-label, multicentre, randomised, adaptive platform trial of the safety and efficacy of several therapies, including antiviral therapies, versus control in mild/moderate cases of COVID-19. ANTICOV Master Clinical Study Protocol, 1, 1–108.
   Google Scholar
• Arnold, S., 2022. Randomized, multi-arm phase II trial of novel agents for treatment of high-risk COVID-19 positive patients (clinical trial registration No. NCT04374019). https://clinicaltrials.gov/ct2/show/study/NCT04374019
   Google Scholar
• Bandyopadhyaya, R., Lall, A.A., and Friedlander, S.K., 2004. Aerosol dynamics and the synthesis of fine solid particles. Powder technology, 139 (3), 193–199.
   Web of Science ®Google Scholar
• Barnabas, R.V., et al., 2021. Hydroxychloroquine as postexposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 infection. Annals of internal medicine, 174 (3), 344–352.
   Google Scholar
• Bramante, C.T., COVID-OUT Trial Team., et al., 2022. Randomized trial of metformin, ivermectin, and fluvoxamine for Covid-19. The New England journal of medicine, 387 (7), 599–610.
   PubMed Web of Science ®Google Scholar
• Butler, C.C., et al., 2021. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. The lancet, 397 (10279), 1063–1074.
   Google Scholar
• Cairns, D.M., et al., 2022. Efficacy of niclosamide vs placebo in SARS-CoV-2 respiratory viral clearance, viral shedding, and duration of symptoms among patients with mild to moderate COVID-19: a phase 2 randomized clinical trial. JAMA network open, 5 (2), e2144942.
   Google Scholar
• Cavalcanti, A.B., Coalition Covid-19 Brazil I Investigators., et al., 2020. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. The New England journal of medicine, 383 (21), 2041–2052.
   PubMed Web of Science ®Google Scholar
• Clemency, B.M., et al., 2022. Efficacy of inhaled ciclesonide for outpatient treatment of adolescents and adults with symptomatic COVID-19: a randomized clinical trial. JAMA internal medicine, 182 (1), 42–49.
   PubMed Web of Science ®Google Scholar
• Danhier, F., et al., 2012. PLGA-based nanoparticles: an overview of biomedical applications. Journal of controlled release, 161 (2), 505–522.
   PubMed Web of Science ®Google Scholar
• Dasankoppa, F., et al., 2017. Design, formulation, and evaluation of in situ gelling ophthalmic drug delivery system comprising anionic and nonionic polymers. Indian journal of health sciences and biomedical research, 10 (3), 323.
   Google Scholar
• Declercq, J., et al., 2020. Zilucoplan in patients with acute hypoxic respiratory failure due to COVID-19 (ZILU-COV): a structured summary of a study protocol for a randomised controlled trial. Trials, 21 (1), 934.
   PubMedGoogle Scholar
• Echeverría-Esnal, D., et al., 2021. Azithromycin in the treatment of COVID-19: a review. Expert review of anti-infective therapy, 19 (2), 147–163.
   PubMed Web of Science ®Google Scholar
• Eli Lilly and Company, 2022. A randomized, double-blind, placebo-controlled, phase 2 study to evaluate the efficacy and safety of mono and combination therapy with monoclonal antibodies in participants with mild to moderate COVID-19 illness (BLAZE-4) (clinical trial registration No. NCT04634409). https://clinicaltrials.gov/ct2/show/study/NCT04634409
   Google Scholar
• Ezer, N., et al., 2021. Inhaled and intranasal ciclesonide for the treatment of Covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial. British medical journal, 375, e068060.
   Google Scholar
• Fonte, P., et al., 2011. Chitosan-coated solid lipid nanoparticles enhance the oral absorption of insulin. Drug delivery and translational research, 1 (4), 299–308.
   PubMed Web of Science ®Google Scholar
• Furtado, R.H.M., et al., 2020. Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. The lancet, 396 (10256), 959–967.
   Web of Science ®Google Scholar
• Garcia-Contreras, L., and Hickey, A.J., 2002. Pharmaceutical and biotechnological aerosols for cystic fibrosis therapy. Advanced drug delivery reviews, 54 (11), 1491–1504.
   PubMed Web of Science ®Google Scholar
• Gentile, P., et al., 2014. An overview of poly(lactic-co-glycolic) acid (PLGA)-based biomaterials for bone tissue engineering. International journal of molecular sciences, 15 (3), 3640–3659.
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline, 2022. A randomized, double-blind, placebo-controlled, study evaluating the efficacy and safety of otilimab IV in patients with severe pulmonary COVID-19 related disease (clinical trial registration No. NCT04376684). https://clinicaltrials.gov/ct2/show/study/NCT04376684
   Google Scholar
• Gottlieb, R.L., GS-US-540-9012 (PINETREE) Investigators., et al., 2022. Early remdesivir to prevent progression to severe Covid-19 in outpatients. The New England journal of medicine, 386 (4), 305–315.
   PubMed Web of Science ®Google Scholar
• Grau, M.J., Kayser, O., and Müller, R.H., 2000. Nanosuspensions of poorly soluble drugs—reproducibility of small scale production. International journal of pharmaceutics, 196 (2), 155–159.
   PubMed Web of Science ®Google Scholar
• Guimarães, P.O., STOP-COVID Trial Investigators., et al., 2021. Tofacitinib in patients hospitalized with Covid-19 pneumonia. The New England journal of medicine, 385 (5), 406–415.
   PubMed Web of Science ®Google Scholar
• Günday Türeli, N., Türeli, A.E., and Schneider, M., 2016. Optimization of ciprofloxacin complex loaded PLGA nanoparticles for pulmonary treatment of cystic fibrosis infections: design of experiments approach. International journal of pharmaceutics, 515 (1–2), 343–351.
   PubMed Web of Science ®Google Scholar
• Hammond, J., EPIC-HR Investigators., et al., 2022. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. The New England journal of medicine, 386 (15), 1397–1408.
   PubMed Web of Science ®Google Scholar
• Han, R., Papadopoulos, G., and Greenspan, B.J., 2002. Investigation of powder dispersion inside a SPIROSR dry powder inhaler using particle image velocimetry. Powder technology, 125 (2–3), 266–278.
   Web of Science ®Google Scholar
• Hassan, M.S. and Lau, R.W.M., 2009. Effect of particle shape on dry particle inhalation: study of flowability, aerosolization, and deposition properties. AAPS PharmSciTech, 10 (4), 1252–1262.
   PubMed Web of Science ®Google Scholar
• Hayes, D., Jr., et al., 2010. Aerosolized vancomycin for the treatment of MRSA after lung transplantation. Respirology, 15 (1), 184–186.
   PubMed Web of Science ®Google Scholar
• Hickey, A.J., et al., 2006. Inhaled azithromycin therapy. Journal of aerosol medicine, 19 (1), 54–60.
   PubMedGoogle Scholar
• Hinks, T.S.C., et al., 2021. Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial. The lancet-respiratory medicine, 9 (10), 1130–1140.
   PubMed Web of Science ®Google Scholar
• Hung, I.F.-N., et al., 2020. Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. The lancet, 395 (10238), 1695–1704.
   Web of Science ®Google Scholar
• Kanoh, S., and Rubin, B.K., 2010. Mechanisms of action and clinical application of macrolides as immunomodulatory medications. Clinical microbiology reviews, 23 (3), 590–615.
   PubMed Web of Science ®Google Scholar
• Keck, C., and Muller, R., 2006. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. European journal of pharmaceutics and biopharmaceutics, 62 (1), 3–16.
   PubMed Web of Science ®Google Scholar
• Kocbek, P., Baumgartner, S., and Kristl, J., 2006. Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs. International journal of pharmaceutics, 312 (1–2), 179–186.
   PubMed Web of Science ®Google Scholar
• Kumar, V., et al., 2021. COVID-19 pandemic: mechanism, diagnosis, and treatment. Journal of chemical technology & biotechnology, 96 (2), 299–308.
   Web of Science ®Google Scholar
• Li, X., et al., 2014a. Design, characterization, and aerosol dispersion performance modeling of advanced co-spray dried antibiotics with mannitol as respirable microparticles/nanoparticles for targeted pulmonary delivery as dry powder inhalers. Journal of pharmaceutical sciences, 103 (9), 2937–2949.
   PubMed Web of Science ®Google Scholar
• Li, X., et al., 2014b. Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery. European journal of pharmaceutical sciences, 52, 191–205.
   PubMed Web of Science ®Google Scholar
• Lode, H., 1991. The pharmacokinetics of azithromycin and their clinical significance. European journal of clinical microbiology & infectious diseases, 10 (10), 807–812.
   PubMed Web of Science ®Google Scholar
• Luke, D.R., and Foulds, G., 1997. Disposition of oral azithromycin in humans*. Clinical pharmacology and therapeutics, 61 (6), 641–648.
   PubMed Web of Science ®Google Scholar
• Mangal, S., et al., 2018. Physico-chemical properties, aerosolization and dissolution of co-spray dried azithromycin particles with L-leucine for inhalation. Pharmaceutical research, 35 (2), 28.
   PubMed Web of Science ®Google Scholar
• Mantero, V., et al., 2021. COVID‐19 in dimethyl fumarate‐treated patients with multiple sclerosis. Journal of neurology, 268 (6), 2023–2025.
   PubMed Web of Science ®Google Scholar
• McEneny-King, A.C., Monteleone, J.P.R., Kazani, S.D., and Ortiz, S.R., 2021. Pharmacokinetic and pharmacodynamic evaluation of ravulizumab in adults with severe coronavirus disease 2019. Infectious diseases and therapy, 10, 1045–1054.
   Google Scholar
• Mittal, G., et al., 2007. Estradiol loaded PLGA nanoparticles for oral administration: Effect of polymer molecular weight and copolymer composition on release behavior in vitro and in vivo. Journal of controlled release, 119 (1), 77–85.
   PubMed Web of Science ®Google Scholar
• Müller, R.H., and Jacobs, C., 2002. Buparvaquone mucoadhesive nanosuspension: preparation, optimisation and long-term stability. International journal of pharmaceutics, 237 (1–2), 151–161.
   PubMed Web of Science ®Google Scholar
• Müller, R.H., and Peters, K., 1998. Nanosuspensions for the formulation of poorly soluble drugs. International journal of pharmaceutics, 160 (2), 229–237.
   Web of Science ®Google Scholar
• National Institute for Health and Care Excellence, 2022. COVID-19 rapid guideline: managing COVID-19. National Institute for Health and Care Excellence: Clinical Guideline No.191. (ISBN-13: 978-1-4731-4074-5).
   Google Scholar
• National Institute of Allergy and Infectious Diseases (NIAID), 2022. A multicenter platform trial of putative therapeutics for the treatment of COVID-19 in hospitalized adults (Clinical trial registration No. NCT04583956). https://www.clinicaltrials.gov/ct2/show/study/NCT04583956
   Google Scholar
• Oldenburg, C.E., et al., 2021. Effect of oral azithromycin vs. placebo on COVID-19 symptoms in outpatients with SARS-CoV-2 infection: a randomized clinical trial. JAMA, 326 (6), 490–498.
   PubMed Web of Science ®Google Scholar
• Oliver, M.E., and Hinks, T.S.C., 2021. Azithromycin in viral infections. Reviews in medical virology, 31 (2), e2163.
   PubMed Web of Science ®Google Scholar
• Perez, C., et al., 2001. Poly(lactic acid)-poly(ethylene glycol) nanoparticles as new carriers for the delivery of plasmid DNA. J. Controlled release,75 (1–2), 211–224.
   PubMed Web of Science ®Google Scholar
• Profact Inc., 2022. A phase 2 screening study of candidate non-prescription treatments for COVID-19: a patient-driven, randomized, factorial study evaluating patient-reported outcomes (PROFACT-01). (Clinical trial registration no. NCT04621149). https://clinicaltrials.gov/ct2/show/study/NCT04621149
   Google Scholar
• Rizzardini, G., 2020. A multi-center, randomized, double-blind, placebo-controlled, phase III clinical study evaluating the efficacy and safety of favipiravir in the treatment of patients with COVID-19-moderate type. (Clinical trial registration no. NCT04336904). https://clinicaltrials.gov/ct2/show/NCT04336904
   Google Scholar
• Rogueda, P.G., and Traini, D., 2007. The nanoscale in pulmonary delivery. Part 1: deposition, fate, toxicology and effects. Expert opinion on drug delivery, 4 (6), 595–606.
   PubMed Web of Science ®Google Scholar
• Ruan, X., et al., 2022. Remdesivir powders manufactured by jet milling for potential pulmonary treatment of COVID-19. Pharmaceutical development and technology, 27 (6), 635–645.
   PubMed Web of Science ®Google Scholar
• Sahakijpijarn, S., et al., 2020. Development of remdesivir as a dry powder for inhalation by thin film freezing. Pharmaceutics, 12 (11), 1002.
   PubMed Web of Science ®Google Scholar
• Santoro, F., et al., 2022. Antiplatelet therapy and outcome in COVID-19: the health outcome predictive evaluation registry. Heart, 108 (2), 130–136.
   PubMed Web of Science ®Google Scholar
• Sekhavati, E., et al., 2020. Safety and effectiveness of azithromycin in patients with COVID-19: an open-label randomised trial. International journal of antimicrobial agents, 56 (4), 106143.
   PubMed Web of Science ®Google Scholar
• Seyfarth, F., et al., 2008. Antifungal effect of high- and low-molecular-weight chitosan hydrochloride, carboxymethyl chitosan, chitosan oligosaccharide and N-acetyl-d-glucosamine against Candida albicans, Candida krusei and Candida glabrata. International journal of pharmaceutics, 353 (1–2), 139–148.
   PubMed Web of Science ®Google Scholar
• Sharma, S., et al., 2016. PLGA-based nanoparticles: a new paradigm in biomedical applications. TrAC trends in analytical chemistry, 80, 30–40.
   Web of Science ®Google Scholar
• Shoumann, W.M., et al., 2021. Use of ivermectin as a potential chemoprophylaxis for COVID-19 in Egypt: a randomised clinical trial. Journal of clinical and diagnostic research, 15 (2), OC27–OC32.
   Web of Science ®Google Scholar
• Sun, D., 2020. Remdesivir for treatment of COVID-19: combination of pulmonary and IV administration may offer adittional benefit. The AAPS journal, 22 (4), 77.
   PubMed Web of Science ®Google Scholar
• The COVID STEROID 2 Trial Group, 2021. Effect of 12 mg vs 6 mg of dexamethasone on the number of days alive without life support in adults with COVID-19 and severe hypoxemia: the COVID steroid 2 randomized trial. JAMA, 326 (18), 1807–1817.
   Web of Science ®Google Scholar
• The RECOVERY Collaborative Group, 2021. Dexamethasone in hospitalized patients with Covid-19. New England journal of medicine, 384 (8), 693–704.
   Web of Science ®Google Scholar
• Touret, F., et al., 2020. In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication. Scientific reports, 10 (1), 13093.
   PubMed Web of Science ®Google Scholar
• Wilkinson, T., et al., 2020. ACCORD: a multicentre, seamless, phase 2 adaptive randomisation platform study to assess the efficacy and safety of multiple candidate agents for the treatment of COVID-19 in hospitalised patients: a structured summary of a study protocol for a randomised controlled trial. Trials, 21 (1), 691.
   Google Scholar
• University of Dundee, 2021. A randomised double-blind placebo-controlled trial of brensocatib (INS1007) in patients with severe COVID-19 (Clinical trial registration No. NCT04817332). https://clinicaltrials.gov/ct2/show/study/NCT04817332
   Google Scholar
• Smieszek, S.P., et al., 2021. Assessing the potential correlation of polymorphisms in the IL6R with relative IL6 elevation in severely ill COVID-19 patients’. Cytokine, 148, 155662.
   Google Scholar
• Vartak, R., et al., 2021. Aerosolized nanoliposomal carrier of remdesivir: an effective alternative for COVID-19 treatment in vitro. Nanomedicine, 16 (14), 1187–1202.
   PubMed Web of Science ®Google Scholar
• Young, P.M., et al., 2015. Multi-breath dry powder inhaler for delivery of cohesive powders in the treatment of bronchiectasis. Drug development and industrial pharmacy, 41 (5), 859–865.
   PubMed Web of Science ®Google Scholar